Revelation Biosciences, Inc., (REVB): Price and Financial Metrics
REVB Price/Volume Stats
Current price | $4.24 | 52-week high | $69.44 |
Prev. close | $4.25 | 52-week low | $3.34 |
Day low | $4.03 | Volume | 61,304 |
Day high | $4.37 | Avg. volume | 370,648 |
50-day MA | $6.25 | Dividend yield | N/A |
200-day MA | $18.00 | Market Cap | 1.14M |
REVB Stock Price Chart Interactive Chart >
Revelation Biosciences, Inc., (REVB) Company Bio
Revelation Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of immunologic-based therapeutics and diagnostics for the prevention and treatment of disease. The company's lead therapeutic candidate is REVTx-99, an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses, such as SARS-CoV-2 comprising its variants, influenza A and B, parainfluenza, rhinovirus, and RSV, as well as is being developed for other indications comprising allergic rhinitis and chronic nasal congestion. It also develops REVTx-200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for immunity; and REVDx-501, a rapid home use diagnostic to detect respiratory viral infection. The company was founded in 2019 and is based in New York, New York.
REVB Price Returns
1-mo | -43.70% |
3-mo | -67.00% |
6-mo | -69.22% |
1-year | -91.17% |
3-year | -99.99% |
5-year | N/A |
YTD | -42.52% |
2024 | -96.93% |
2023 | -92.47% |
2022 | -98.14% |
2021 | 1.49% |
2020 | N/A |
Loading social stream, please wait...